# Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

> **NCT03187795** · PHASE2 · UNKNOWN · sponsor: **Kessler Foundation** · enrollment: 62 (estimated)

## Conditions studied

- Spinal Cord Injuries
- Urinary Bladder, Neurogenic

## Interventions

- **DRUG:** Oxybutynin Chloride IR
- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT03187795
- **Lead sponsor:** Kessler Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-03
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187795, "Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03187795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*